JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Arcus Biosciences Inc

Fechado

SetorSaúde

16.76 0.96

Visão Geral

Variação de preço das ações

24h

Atual

Mín

16.4

Máximo

16.95

Indicadores-chave

By Trading Economics

Vendas

132M

160M

Funcionários

627

EBITDA

126M

4M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+79.11% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

882M

1.9B

Abertura anterior

15.8

Fecho anterior

16.76

Pontuação Técnica

By Trading Central

Confiança

Neutral Evidence

Arcus Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de out. de 2025, 20:49 UTC

Ganhos

Correction to Thermo Fisher Article on Oct. 22

23 de out. de 2025, 23:51 UTC

Conversa de Mercado

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 de out. de 2025, 23:49 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 de out. de 2025, 23:49 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 de out. de 2025, 23:37 UTC

Conversa de Mercado

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 de out. de 2025, 22:58 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

23 de out. de 2025, 22:57 UTC

Conversa de Mercado

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 de out. de 2025, 22:49 UTC

Aquisições, Fusões, Aquisições de Empresas

How Trump Sparked a New Era of State Capitalism -2-

23 de out. de 2025, 22:49 UTC

Aquisições, Fusões, Aquisições de Empresas

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 de out. de 2025, 22:17 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 de out. de 2025, 21:41 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 de out. de 2025, 21:05 UTC

Ganhos

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 de out. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

23 de out. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

23 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

23 de out. de 2025, 20:35 UTC

Ganhos

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 de out. de 2025, 20:28 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 de out. de 2025, 20:15 UTC

Conversa de Mercado
Ganhos

Global Commodities Roundup: Market Talk

23 de out. de 2025, 20:10 UTC

Ganhos

Newmont Mining 3Q Adj EPS $1.71

23 de out. de 2025, 20:10 UTC

Ganhos

Newmont Mining 3Q Sales $5.52B

23 de out. de 2025, 20:10 UTC

Ganhos

Newmont Mining 3Q EPS $1.67

23 de out. de 2025, 20:09 UTC

Ganhos

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 de out. de 2025, 20:07 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

23 de out. de 2025, 20:07 UTC

Conversa de Mercado
Ganhos

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 de out. de 2025, 20:07 UTC

Ganhos

Blackstone Looks to IPOs for Investment Exits -- Update

23 de out. de 2025, 20:05 UTC

Ganhos

Intel 3Q Gross Margin 38.2% >INTC

23 de out. de 2025, 20:04 UTC

Ganhos

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 de out. de 2025, 20:04 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 de out. de 2025, 20:04 UTC

Ganhos

Intel: 4Q Guidance Excludes Altera >INTC

23 de out. de 2025, 20:04 UTC

Ganhos

Intel Sees 4Q Adj EPS 8c >INTC

Comparação entre Pares

Variação de preço

Arcus Biosciences Inc Previsão

Preço-alvo

By TipRanks

79.11% parte superior

Previsão para 12 meses

Média 32.33 USD  79.11%

Máximo 54 USD

Mínimo 14 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcus Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

12 ratings

11

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

8.01 / 8.75Suporte e Resistência

Curto Prazo

Neutral Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat